| payload |
{"created_at":"2026-04-21T18:18:22.267 {"created_at":"2026-04-21T18:18:22.267745+00:00","signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","url":"https://www.nasdaq.com/articles/regeneron-reports-positive-phase-3-data-cemdisiran-myasthenia-gravis","value":{"fp":"ec8f4489ba25003e","kind":"unusual_volume","published_at":"2026-04-21T17:55:11+00:00","source":"Nasdaq Markets","summary":"(RTTNews) - Regeneron Pharmaceuticals (REGN) reported positive Phase 3 results for cemdisiran in Generalized Myasthenia Gravis, with the NIMBLE trial meeting primary and key secondary endpoints at 24 weeks.","tickers":["REGN"],"title":"Regeneron Reports Positive Phase 3 Data For Cemdisiran In Myasthenia Gravis","url":"https://www.nasdaq.com/articles/regeneron-reports-positive-phase-3-data-cemdisiran-myasthenia-gravis"}}... |